Search
Now showing items 1-6 of 6
Involvement of hepatic macrophages in the antifibrotic effect of IGF-I_overexpressing mesenchymal stromal cells.
(BMC (part of Springer Nature), 2016-11-22)
BACKGROUND:
Cirrhosis is a major health problem worldwide and new therapies are needed. Hepatic macrophages (hMø) have a pivotal role in liver fibrosis, being able to act in both its promotion and its resolution. It is ...
A Comprensive study of epigenetic alterations in hepatocellular carcicoma identifies potencial therapeutic targets.
(Elsevier B.V. All rights reserved, 2019-07-01)
Abstract
Background & aims: A causal link has recently been established between epigenetic alterations and hepatocarcinogenesis, indicating that epigenetic inhibition may have therapeutic potential. We aimed to identify ...
Development of an Improved Guanidine-Based Rac1 Inhibitor with in vivo Activity against Non-Small Cell Lung Cancer
(Wiley, 2021-03)
Abstract
The Rho GTPase Rac1 is involved in the control of cytoskeleton reorganization and other fundamental cellular functions. Aberrant activity of Rac1 and its regulators is common in human cancer. In particular, ...
SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism
(Wiley, 2021-07)
Abstract
Background and aims: Non-alcoholic fatty liver (NAFLD) and its more serious form non-alcoholic steatohepatitis increase risk of hepatocellular carcinoma (HCC). Lipid metabolic alterations and its role in HCC ...
4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice
(Nature Research, 2021-03-01)
Hepatocellular carcinoma (HCC) arises in the setting of advanced liver fibrosis, a dynamic and complex inflammatory disease. The tumor microenvironment (TME) is a mixture of cellular components including cancer cells, ...
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
(AASLD, 2020-09)
Potential conflict of interest: Nothing to report.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer‐related death worldwide, and its mortality is increasing steadily.1 HCC incidence has grown in the ...